Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Hospital Acquired Disease Testing Market: By Indication: UTI (Urinary Tract Infection), SSI, Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus); Regional Analysis; Historical Market and Forecast (2015-2025); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Hospital Acquired Disease Testing Market Outlook 

The global hospital acquired disease testing market attained a value of USD 1,020.5 million in 2019. The market is further anticipated to reach USD 2,538 million by 2025 while registering a CAGR of 16.4% over the forecast period of 2020-2025.

On the basis of the indication, the urinary tract infection segment is estimated to be the largest indication segment. The segment growth is primarily attributed to the rising incidences of immune suppression accompanied by urologic abnormality due to the consumption of unhealthy food, alcohol, and smoking.

Regionally, North America is anticipated to dominate the market in 2019, owing to the increasing reimbursement policies and favourable government initiatives towards hospital acquired (nosocomial) infections.

 

Properties and Applications 

A hospital acquired infection (HAI) or diseases or nosocomial infection is an infection which is acquired from the hospital or the clinical surrounding including nursing homes, and rehabilitation centres, among others. The incubation period of the nosocomial infection generally varies between 48 hours to 4 days. The prime reason behind the cause of HAI is the lack of proper hygiene in the hospital or clinical environment by the internal staff. Also, other factors that can be attributed to the growth of HAI include below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the commonly occurring nosocomial infections include pneumonia, urinary tract infections (UTI), and primary bloodstream infections. 

On the basis of indication, the market is segmented into:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

The EMR report looks into the regional markets of hospital acquired disease testing like Europe, the Asia Pacific, North America, Latin America, and the Middle East and Africa.

 

Market Analysis 

With the increasing global population, rapid urbanisation, and modernisation of healthcare infrastructure, there has been a significant increase in the number of health care facilities. This has led to the rising incidence of HAIs, which, in turn, is propelling the demand for hospital acquired disease tests. The rising adoption of advanced technologies for preventing, diagnosing, and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridisation, is further expected to augment the market growth.

Moreover, the growing awareness of HAIs among patients and stringent government regulations to penalize hospitals with a high incidence of HAIs are some of the other factors that are strengthening the growth of the market. Increasing research and development activities for developing new techniques, coupled with various mergers and acquisitions and strategic partnerships by various manufacturers, are expected to create potential revenue opportunities for players operating in the market over the forecast period.

 

Competitive Landscape 

The report presents a detailed analysis of the following key players in the global hospital acquired disease testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Siemens Healthcare GmbH
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Hospital Acquired Disease Testing Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Hospital Acquired Disease Testing Historical Market (2015-2019) 
    8.3    Global Hospital Acquired Disease Testing Market Forecast (2020-2025)
    8.4    Global Hospital Acquired Disease Testing Market by Indication
        8.4.1    UTI (Urinary Tract Infection)  
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2015-2019)
            8.4.1.3    Forecast Trend (2020-2025)
        8.4.2    SSI (Surgical Site Infection) 
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2015-2019)
            8.4.2.3    Forecast Trend (2020-2025)
        8.4.3    Pneumonia 
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2015-2019)
            8.4.3.3    Forecast Trend (2020-2025)
        8.4.4    Bloodstream Infections 
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2015-2019)
            8.4.4.3    Forecast Trend (2020-2025)
        8.4.5    MRSA (Methicillin-Resistant Staphylococcus Aureus)  
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2015-2019)
            8.4.5.3    Forecast Trend (2020-2025)
        8.4.6    Others
    8.5    Global Hospital Acquired Disease Testing Market by Region
        8.5.1    Market Share
            8.5.1.1    North America
            8.5.1.2    Europe
            8.5.1.3    Asia Pacific
            8.5.1.4    Latin America
            8.5.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2015-2019)
        9.1.2    Forecast Trend (2020-2025)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2015-2019)
        9.2.2    Forecast Trend (2020-2025)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2015-2019)
        9.3.2    Forecast Trend (2020-2025)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2015-2019)
        9.4.2    Forecast Trend (2020-2025)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2015-2019)
        9.5.2    Forecast Trend (2020-2025)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Company Profiles
        13.3.1    Abbott Laboratories
            13.3.1.1    Company Overview
            13.3.1.2    Demographic Reach and Achievements
            13.3.1.3    Certifications
        13.3.2    Becton, Dickinson and Company
            13.3.2.1    Company Overview
            13.3.2.2    Demographic Reach and Achievements
            13.3.2.3    Certifications
        13.3.3    F. Hoffmann-La Roche Ltd.
            13.3.3.1    Company Overview
            13.3.3.2    Demographic Reach and Achievements
            13.3.3.3    Certifications
        13.3.4    Hologic, Inc.
            13.3.4.1    Company Overview
            13.3.4.2    Demographic Reach and Achievements
            13.3.4.3    Certifications
        13.3.5    Siemens Healthcare GmbH
            13.3.5.1    Company Overview
            13.3.5.2    Demographic Reach and Achievements
            13.3.5.3    Certifications
        13.3.6    Others
14    Industry Events and Developments


List of Figures and Tables

1.    Global Hospital Acquired Disease Testing Market: Key Industry Highlights, 2015 and 2025
2.    Global Hospital Acquired Disease Testing Historical Market: Breakup by Indication (USD Million), 2015-2019
3.    Global Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (USD Million), 2020-2025
4.    Global Hospital Acquired Disease Testing Historical Market: Breakup by Region (USD Million), 2015-2019
5.    Global Hospital Acquired Disease Testing Market Forecast: Breakup by Region (USD Million), 2020-2025
6.    North America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2015-2019
7.    North America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2020-2025
8.    Europe Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2015-2019
9.    Europe Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2020-2025
10.    Asia Pacific Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2015-2019
11.    Asia Pacific Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2020-2025
12.    Latin America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2015-2019
13.    Latin America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2020-2025
14.    Middle East and Africa Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2015-2019
15.    Middle East and Africa Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2020-2025
16.    Global Hospital Acquired Disease Testing Market Structure

Key Questions Answered in the Report

In 2019, the global hospital acquired disease testing market attained a value of nearly USD 1,020.5 million.

In the forecast period of 2020-2025, the market is expected to grow at a CAGR of 16.4%.

By 2025, the market is expected to attain a value of USD 2,538 million.

The major drivers of the industry, such as the growing modernisation of healthcare, increasing adoption of advanced technologies, and rising investments into the R&D, are aiding the market growth.

The key trends guiding the growth of the market include the stringent government regulations and rising awareness among the patients about hospital acquired diseases.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America leading the market. 

The leading indication type in the industry is UTI (urinary tract infection).

The major players in the industry are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.

Analyst Review

The global hospital acquired disease testing market attained a value of USD 1,020.5 million in 2019, driven by the modernisation of the healthcare infrastructure. Aided by technological advancements, the market is expected to witness a further growth in the forecast period of 2020-2025, growing at a CAGR of 16.4%. The market is projected to reach USD 2,538 million by 2025. 

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on indication, the market can be segmented into UTI (urinary tract infection), SSI (surgical site infection), pneumonia, bloodstream infections, and MRSA (methicillin-resistant staphylococcus aureus), among others, with UTI (urinary tract infection) accounting for the largest market share. The major regional markets for hospital acquired disease are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market. The key players in the above market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.  Global Hospital Acquired Disease Testing Market

Purchase Full Report

Mini Report

$ 1099     $999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Single User License

$ 2999     $1999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Five User License

$ 3999     $2999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Corporate License

$ 4999     $3999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Anti-Fibrinolytic Drugs Market Report and Forecast 2020-2025


Global Trenbolone Enanthate Market Report and Forecast 2020-2025


Global Alprazolam Powder Market Report and Forecast 2020-2025


Global Legal Marijuana Market Report and Forecast 2020-2025



NEWSLETTER